Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 3/20 | 0.42 |
| ▸ | AXL | P30530 | 2/20 | 0.42 |
| ▸ | CCNK | O75909 | 2/20 | 0.33 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CFB | P00751 | 3/20 | 0.33 |
| ▸ | CIT | O14578 | 2/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.30 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6127940 | 0.86 | AXL (0.42) | PRKCIAXLCCNKCDK12BTK | |
| SCHEMBL8736950 | 0.84 | TAAR1 (0.36) | PRKCIAXLCCNKCDK12BTK | |
| SCHEMBL2628879 | 0.77 | PRKCI (0.47) | PRKCIAXLCCNKCDK12BTK | |
| SCHEMBL8737516 | 0.76 | BTK (0.36) | PRKCIAXLBTKJAK3TTBK1 | |
| SCHEMBL2628869 | 0.74 | AXL (0.53) | PRKCIAXLCCNKCDK12CFB | |
| SCHEMBL21986162 | 0.74 | AXL (0.44) | PRKCIAXLCCNKCDK12CFB | |
| SCHEMBL21726013 | 0.74 | AXL (0.38) | PRKCIAXLCCNKCDK12BTK | |
| SCHEMBL27290679 | 0.71 | AXL (0.42) | PRKCIAXLCCNKCDK12CFB | |
| SCHEMBL18819909 | 0.71 | BTK (0.33) | BTK | |
| SCHEMBL13154921 | 0.71 | PLAU (0.46) | CCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | PRKCI 325/4885AXL 4135/4885CCNK 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.